WhiteLab Genomics

whitelabgx.com →

-46%

est. 2Y upside i

HealthcareSeries A

Unleashing the potential of DNA and RNA based therapies using AI

Rank

#340

Sector

Biotechnology, AI in Drug Discovery

Est. Liquidity

~4Y

Data Quality

Data: Medium

WhiteLab Genomics operates in a high-growth AI in drug discovery market (TAM $8.5B, growing ~31% YoY) with a strong competitive moat through its proprietary AI platform.

Last updated: March 10, 2026

Bull (28%)+350%

WhiteLab Genomics' proprietary AI platform gains significant traction, securing major partnerships with multiple top-tier pharmaceutical companies and expanding its platform-as-a-service offerings. This drives revenue to $50M+ by 2028, justifying a $450M+ valuation at a premium multiple, well above the current $100M.

Base (44%)+120%

The company continues to grow steadily, expanding its customer base and demonstrating strong efficacy in accelerating genomic therapy discovery. It achieves $20-30M in revenue by 2028, leading to a successful Series C or acquisition at a valuation of $220M, reflecting solid execution in a competitive market.

Bear (28%)-80%

Intense competition from well-funded incumbents and consolidating AI drug discovery players leads to pricing pressure and slower-than-expected customer acquisition. Regulatory hurdles or challenges in demonstrating clear ROI for its platform result in stalled growth, a down round to $20M, and significant loss of common stock value given the $11M liquidation preference.

Est. time to liquidity~3.5 years

Preference Stack Risk

moderate

Funding Intensity

11%

Investors hold $11M in liquidation preferences ahead of common stock. In an exit at or below $11M, common shareholders would receive little to nothing.

Dilution Risk

moderate

As a Series A company, WhiteLab Genomics will likely require at least one to two more significant funding rounds (Series B, Series C) before an exit, which will lead to further dilution for existing common shareholders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for WhiteLab Genomics' equity.

Other — 1 role

  • Careers · Paris, Boston, Montréal
View all 1 open roles at WhiteLab Genomics →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on WhiteLab Genomics's data — designed to show you've done your homework.

  • 1

    “Given the trend of consolidation in the AI drug discovery space, how does WhiteLab Genomics plan to maintain its competitive edge against larger, well-funded players like Recursion Pharmaceuticals (post-Exscientia acquisition) and incumbents building their own AI platforms?”

  • 2

    “With the AI in drug discovery market projected to grow significantly, what are WhiteLab Genomics' specific revenue targets and customer acquisition strategies for the next 24 months, particularly following its expansion into the US?”

  • 3

    “As a Series A company, what is the anticipated timeline for future funding rounds, and how is WhiteLab Genomics thinking about potential liquidity events for employees over a 2-4 year horizon, considering the current preference stack?”

Community

Valuation Sentiment

Our model estimates -46% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.